MaaT Pharma SA (MAAT.PA)
EUR 6.04
(-2.27%)
EUR 6.04
(-2.27%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 22.46 Million EUR | 25.4% |
| 2022 | 17.91 Million EUR | 87.32% |
| 2021 | 9.56 Million EUR | 14.69% |
| 2020 | 8.33 Million EUR | -34.52% |
| 2019 | 12.73 Million EUR | 175.89% |
| 2018 | 4.61 Million EUR | 15.57% |
| 2017 | 3.99 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 25.31 Million EUR | 0.0% |
| 2024 Q1 | 25.31 Million EUR | 12.67% |
| 2023 FY | 22.46 Million EUR | 25.4% |
| 2023 Q1 | 18.49 Million EUR | 3.23% |
| 2023 Q4 | 22.46 Million EUR | 0.0% |
| 2023 Q3 | 22.46 Million EUR | 21.47% |
| 2023 Q2 | 18.49 Million EUR | 0.0% |
| 2022 Q4 | 17.91 Million EUR | 0.0% |
| 2022 Q3 | 17.91 Million EUR | 28.4% |
| 2022 Q2 | 13.95 Million EUR | 0.01% |
| 2022 Q1 | 13.95 Million EUR | 45.88% |
| 2022 FY | 17.91 Million EUR | 87.32% |
| 2021 Q1 | 9.65 Million EUR | 15.72% |
| 2021 FY | 9.56 Million EUR | 14.69% |
| 2021 Q4 | 9.56 Million EUR | 0.0% |
| 2021 Q3 | 9.56 Million EUR | -0.88% |
| 2021 Q2 | 9.64 Million EUR | -0.01% |
| 2020 Q4 | 8.33 Million EUR | 0.0% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 Q3 | 8.33 Million EUR | 0.0% |
| 2020 FY | 8.33 Million EUR | -34.52% |
| 2019 FY | 12.73 Million EUR | 175.89% |
| 2018 FY | 4.61 Million EUR | 15.57% |
| 2017 FY | 3.99 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -225.014% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 82.858% |
| Adocia SA | 31.87 Million EUR | 29.511% |
| Aelis Farma SA | 13.08 Million EUR | -71.751% |
| Biophytis S.A. | 15.84 Million EUR | -41.744% |
| Advicenne S.A. | 24.37 Million EUR | 7.843% |
| genOway Société anonyme | 14.45 Million EUR | -55.365% |
| IntegraGen SA | 5.97 Million EUR | -275.682% |
| Medesis Pharma S.A. | 6.42 Million EUR | -249.585% |
| Neovacs S.A. | 3.71 Million EUR | -505.179% |
| NFL Biosciences SA | 3.62 Million EUR | -520.463% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -231.227% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -578.679% |
| Sensorion SA | 13.22 Million EUR | -69.839% |
| Theranexus Société Anonyme | 5.01 Million EUR | -347.85% |
| TME Pharma N.V. | 2.78 Million EUR | -706.643% |
| Valbiotis SA | 13.7 Million EUR | -63.882% |
| TheraVet SA | 1.48 Million EUR | -1412.802% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | -9.757% |
| DBV Technologies S.A. | 38.74 Million USD | 42.019% |
| Genfit S.A. | 105.92 Million EUR | 78.791% |
| GeNeuro SA | 20.13 Million EUR | -11.545% |
| Innate Pharma S.A. | 132.29 Million EUR | 83.019% |
| Inventiva S.A. | 101.59 Million EUR | 77.887% |
| MedinCell S.A. | 77.77 Million EUR | 71.114% |
| Nanobiotix S.A. | 95.74 Million EUR | 76.535% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 61.975% |
| Poxel S.A. | 53.9 Million EUR | 58.322% |
| GenSight Biologics S.A. | 34.72 Million EUR | 35.31% |
| Transgene SA | 26.51 Million EUR | 15.281% |
| Valneva SE | 341.14 Million EUR | 93.415% |